62 related articles for article (PubMed ID: 37399010)
1. Outcomes of off-label drug uses in hospitals: a multicentric prospective study.
Danés I; Agustí A; Vallano A; Alerany C; Martínez J; Bosch JA; Ferrer A; Gratacós L; Pérez A; Olmo M; Marron SM; Valderrama A; Bonafont X
Eur J Clin Pharmacol; 2014 Nov; 70(11):1385-93. PubMed ID: 25196202
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 and MIS-C treatment in children-results from an international survey.
Donà D; Minotti C; Masini T; Penazzato M; Van Der Zalm MM; Judd A; Giaquinto C; Lallemant M;
Eur J Pediatr; 2023 Nov; 182(11):5087-5093. PubMed ID: 37672062
[TBL] [Abstract][Full Text] [Related]
3. Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic.
Haulrig MB; Zachariae C; Skov L
Psoriasis (Auckl); 2021; 11():1-20. PubMed ID: 33604269
[TBL] [Abstract][Full Text] [Related]
4. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
5. Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.
Walton M; Wagner JB
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540438
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients.
Liu R; Wang L; Rizzo S; Garmhausen MR; Pal N; Waliany S; McGough S; Lin YG; Huang Z; Neal J; Copping R; Zou J
Cell Rep Med; 2024 Mar; 5(3):101444. PubMed ID: 38428426
[TBL] [Abstract][Full Text] [Related]
7. Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: The single patient study experience.
Revon-Riviere G; Young LC; Stephenson EA; Brodeur-Robb K; Cohen-Gogo S; Deyell R; Lacaze-Masmonteil T; Palmer A; Parekh RS; Whitlock JA; Morgenstern DA
Paediatr Child Health; 2023 Nov; 28(7):399-403. PubMed ID: 37885599
[TBL] [Abstract][Full Text] [Related]
8. Improved access to the innovative anticancer therapies in resource-limited countries: call for global action.
Vaez-Gharamaleki Y; Hosseini MS
Int J Surg; 2024 Mar; ():. PubMed ID: 38537083
[No Abstract] [Full Text] [Related]
9. Novel effects of Ras-MAPK pathogenic variants on the developing human brain and their link to gene expression and inhibition abilities.
Rai B; Naylor PE; Siqueiros-Sanchez M; Wintermark M; Raman MM; Jo B; Reiss AL; Green T
Transl Psychiatry; 2023 Jul; 13(1):245. PubMed ID: 37407569
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.
Hu X; Li W; Zeng K; Xu Z; Li C; Kang Z; Li S; Huang X; Han P; Lin H; Hui AM; Tan Y; Diao L; Li B; Wang X; Wu Z; Lin X
BMC Med; 2023 Jul; 21(1):230. PubMed ID: 37400844
[TBL] [Abstract][Full Text] [Related]
11. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.
Gikandi A; Chi SN; Yeo KK; O'Neill AF; Shulman DS; DuBois SG; Collins NB
Cancer Med; 2024 Apr; 13(8):e7154. PubMed ID: 38629258
[TBL] [Abstract][Full Text] [Related]
12. ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles A; Bautista F; Cañete A; Rubio-San-Simón A; Alonso-Saladrigues A; Hladun R; Rives S; Dapena JL; Fernández JM; Lassaletta Á; Cruz O; Ramírez-Villar G; Fuster JL; de Heredia CD; García-Ariza M; Quiroga E; Del Mar Andrés M; Verdú-Amorós J; Molinés A; Herrero B; López M; Márquez C; Toboso M; Lendínez F; Sirvent JG; Tallón M; Rodríguez G; Acha T; Moreno L; Fernández-Teijeiro A;
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38600340
[TBL] [Abstract][Full Text] [Related]
13. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract][Full Text] [Related]
14. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.
Berlanga P; Ndounga-Diakou LA; Aerts I; Corradini N; Ducassou S; Strullu M; de Carli E; André N; Entz-Werle N; Raimbault S; Roumy M; Renouard M; Gueguen G; Plantaz D; Reguerre Y; Cleirec M; Petit A; Puiseux C; Andry L; Klein S; Bodet D; Kanold J; Briandet C; Halfon-Domenech C; Nelken B; Piguet C; Saumet L; Chastagner P; Benadiba J; Millot F; Pluchart C; Schneider P; Thouvenin S; Gambart M; Serre J; Abbou S; Leruste A; Cayzac H; Gandemer V; Laghouati S; Vassal G
JAMA Netw Open; 2023 Jul; 6(7):e2321568. PubMed ID: 37399010
[TBL] [Abstract][Full Text] [Related]
15. Off-label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center.
Cenna R; Basiricò M; Berchialla P; Bertorello N; Cagnazzo C; Ceolin V; De Luna E; Nolis C; Resente F; Fagioli F
Pediatr Blood Cancer; 2023 Mar; 70(3):e30148. PubMed ID: 36583462
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
[TBL] [Abstract][Full Text] [Related]
18. Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study.
Pratico AD; Longo L; Mansueto S; Gozzo L; Barberi I; Tiralongo V; Salvo V; Falsaperla R; Vitaliti G; La Rosa M; Leonardi S; Rotondo A; Avola N; Sgarlata D; Damiano A; Tirantello M; Anzelmo G; Cipolla D; Rizzo A; Russo A; Ruggieri M; Salomone S; Drago F
Curr Drug Saf; 2018; 13(3):200-207. PubMed ID: 29921210
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
